Alkermes has achieved a significant milestone with its sodium oxybate drug Lumryz, successfully meeting all primary and key secondary endpoints in a phase 3 study targeting a rare sleep disorder. This clinical success follows the company’s strategic $2.37 billion acquisition of Avadel, which has now begun to bear fruit less than a year after the deal was finalized.
The implications of this achievement are substantial for Alkermes, as it not only enhances the company’s portfolio but also strengthens its position in the competitive sleep disorder market. With Lumryz demonstrating efficacy in a niche area, Alkermes may attract increased interest from investors and stakeholders looking for innovative therapies. This development underscores the potential for further growth and expansion within the realm of sleep medicine, positioning Alkermes as a key player in addressing unmet medical needs.
Use the database as your supply chain compass →
